Matricelf

Matricelf is a pioneering biotechnology company focused on regenerating the future of medicine. With a commitment to innovation and patient well-being, Matricelf has developed a groundbreaking technology that enables the production of autologous engineered tissue. This cutting-edge platform utilizes matrix and cells derived from patients' omentum biopsies, showcasing remarkable pre-clinical results across various medical conditions.

Located in Ness Ziona, IL, Matricelf is at the forefront of regenerative medicine. The company's innovative approach gained significant recognition when it licensed the technology that enabled scientists at Tel Aviv University to 3D print a human heart from human cells and matrix for the first time. This achievement underscores Matricelf's dedication to pushing the boundaries of medical science and improving patient outcomes.

Matricelf is planning to conduct its first human clinical trial for Acute Spinal Cord Injury (SCI) in 2024, marking a significant step toward translating its innovative research into tangible therapeutic solutions. Matricelf is poised to revolutionize the field of regenerative medicine with its commitment to excellence. We invite the manager of Matricelf to create a customized and exclusive company showcase and product listing on our platform to further highlight their achievements and drive commercial development.